George B. Zavoico

In a report published Wednesday, MLV & Co analyst George B. Zavoico reiterated a Buy rating on Keryx Biopharmaceuticals (NASDAQ: KERX), and raised the price target from $21.00 to $25.00. In the report, MLV & Co noted, “We are raising our price target for Keryx Biopharmaceuticals, Inc. to $...

In a report published Tuesday, MLV & Co. analyst George B. Zavoico reiterated a Hold rating and $5.00 price target on Cytokinetics (NASDAQ: CYTK). In the report, MLV & Co noted, “Over the weekend, results of the international, randomized, double-blind Phase III PARADIGM-HF trial of LCZ696...

In a report published Friday, MLV & Co analyst George B. Zavoico reiterated a Buy rating and $7.00 price target on XOMA (NASDAQ: XOMA). In the report, MLV & Co noted, “Yesterday afternoon, after markets closed, XOMA Corp. reported 2Q:14 results and updated clinical progress of gevokizumab,...

In a report published Friday, MLV & Co analyst George B. Zavoico upgraded the rating on Geron (NASDAQ: GERN) from Hold to Buy, and raised the price target from $2.00 to $4.25. In the report, MLV & Co noted, “Earlier today, Geron Corp. announced that a partial clinical hold on an...

In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on OXiGENE (NASDAQ: OXGN) with a Buy rating and $7.50 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of OXiGENE with a BUY recommendation and a $7.50 one...

In a report published Tuesday, H.C. Wainwright & Co. analyst George B. Zavoico initiated coverage on Prana Biotechnology (NASDAQ: PRAN) with a Buy rating and $20.50 price target. In the report, H.C. Wainwright & Co. noted, “We are initiating coverage of Prana Biotechnology Ltd. with a BUY...

In a report published Wednesday, MLV & Co. analyst George B. Zavoico downgraded ACADIA Pharmaceuticals (NASDAQ: ACAD) from Buy to Hold, but raised the price target from $18.00 to $20.00. In the report, MLV & Co. noted, “2Q:13 was a transformational quarter for Acadia. On April 11, the...

In a report published Friday, MLV analyst George B. Zavoico initiated coverage on Pluristem Therapeutics (NASDAQ: PSTI) with a Buy rating and $4.50 price target. In the report, MLV noted, “We are initiating coverage of Pluristem Therapeutics based on accumulating, though early, evidence of...